Country Report / New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
HUMAN BioPlazma Kft. is part of Kedrion Biopharma, an international company specializing in the collection and fractionation of blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies.
Kedrion was established in Italy in 2001, but the roots of the companies from which it was born stretch back several decades in the production of blood and plasma derived products. A primarily family-owned business, it places a high value on the welfare of those who benefit from its products and also on the people and communities where it operates. HUMAN BioPlazma became part of Kedrion in 2008, but its own roots extend back to 1922 when its predecessor, the Phylaxia Vaccine Manufacturing company founded its Human Department in Budapest.
HUMAN BioPlazma collects plasma in its own plasma collection centers applying apheresis technology, and also receives plasma for further processing deriving from the excess amounts of whole blood donations, which are not required for transfusiology purposes as the partner of the Hungarian National Blood Transfusion Service.
We have been well-matched to join Kedrion, sharing its commitments and values of quality products, community values and a highly professional workforce.
Contact
H-2100 Gödöllő
Táncsics M. út 80
Hungary
Tel: +36 28 53 22 00
Fax: +36 28 53 22 01
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
